Any current/future new fundraising through debt or equity?

There was no specific mention of any current or planned fundraising through debt or equity in the call. The company highlighted having one of the strongest balance sheets and strong growth momentum. Management expressed being very selective on inorganic growth opportunities rather than urgently pursuing external funding. Upcoming capex plans primarily relate to internal expansions like Plant-6, with details to be shared by end of March. No timelines or concrete plans were provided regarding raising funds through debt or equity at this stage.

Any current/future capex/capital investment/strategic investment?

Upcoming capex primarily focuses on Plant-6, which involves oral solid expansion; currently in layout and machinery selection phase (comment expected by end of March call). Expansion alongside Plant-6 and Plant-2 extension aims to reach INR 1,000 crores revenue. Recent brownfield acquisition of Plant-6 will be built out to support growth. Expansion strategy follows a 2-3 year window rather than a longer 5-6 year timeline. Additional capex expected for Plant-6 to support scaling oral solids beyond current capacity. Continuing investments in existing facilities, including Plant-3 capex

Future growth expectations in sales/revenue/volumes?

Windlas Biotech expects to surpass INR1,000 crores revenue with Plant-6 expansion and injectable capacity ramp-up. Current capacity with Plant-2 expansion supports reaching INR800 crores in oral solids and liquids. Management prefers a 2-3 year expansion window for scalable growth rather than longer timelines. Trade Generics & Institutional vertical grew over 40% YoY in 9 months FY '25; company aims for continued strong growth (25%-30% target indicated). Injectable facility revenue to ramp up from next year, with break-even and positive EBITDA goals, though no specific guidance given. Exports

Future growth expectations in earnings/operating earnings/profits/EPS?

Management refrains from providing explicit earnings or margin guidance for FY '25 and FY '26 due to variability, especially with the new injectable plant ramp-up. The injectable facility's ramp-up is expected to contribute positively over the longer term with a strong leveraging effect on EBITDA and PAT once breakeven is achieved. Trade Generics & Institutional vertical showed strong growth (44% Y-o-Y in 9 months FY '25) with optimism to sustain 25%–30% growth going forward. The company targets maintaining a ROCE around 25%–28%, even with ongoing capex from oral solids expansion (Plant-6) alo

Current/ Expected Orderbook/ Pending Orders?

The injectable facility has already received GMP certification and is undergoing customer audits primarily in Q4 FY '25 and possibly Q1 FY '26. There is already some order book in place for existing production, with products ready for commercialization and out of stability batches. The company sees good momentum and very positive responses from audits and queries on the injectable product portfolio. Exact timing on reaching peak capacity or solid order numbers is uncertain due to the incubation period and the B2B nature of order flow. The company emphasizes a steady buildup in order inflow as

Windlas Biotech LtdQ4 FY25

Windlas Biotech Ltd Q4 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹949P/E: 26.6Market Cap: ₹1.8K Cr

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Windlas Biotech expects to surpass INR1,000 crores revenue with Plant-6 expansion and injectable capacity ramp-up.
→Current capacity with Plant-2 expansion supports reaching INR800 crores in oral solids and liquids.
→Management prefers a 2-3 year expansion window for scalable growth rather than longer timelines.
→Trade Generics & Institutional vertical grew over 40% YoY in 9 months FY '25; company aims for continued strong growth (25%-30% target indicated).
→Injectable facility revenue to ramp up from next year, with break-even and positive EBITDA goals, though no specific guidance given.
→Exports showing steady growth (~23% YoY over 9 months), with plans to accelerate over time.
→Focus on expanding product portfolio, geography, and maintaining quality to fuel growth.
→Inorganic growth pursued cautiously; strong balance sheet allows opportunistic acquisitions but none finalized yet.
→Management expects operating leverage improvements as new investments generate higher incremental profits.

Margin guidance

Category 3

→Management refrains from providing explicit earnings or margin guidance for FY '25 and FY '26 due to variability, especially with the new injectable plant ramp-up.
→The injectable facility's ramp-up is expected to contribute positively over the longer term with a strong leveraging effect on EBITDA and PAT once breakeven is achieved.
→Trade Generics & Institutional vertical showed strong growth (44% Y-o-Y in 9 months FY '25) with optimism to sustain 25%–30% growth going forward.
→The company targets maintaining a ROCE around 25%–28%, even with ongoing capex from oral solids expansion (Plant-6) alongside injectable ramp-up.
→Operating leverage improvements are expected over 3–4 years as cost efficiencies are implemented and capacity utilization increases.
→No specific capex guidance was disclosed, but expansions (Plant-6 and brownfield Plant-6 acquisition) aim to push revenue beyond INR1,000 crores.

3 more insights locked — sign up free to unlock

Fundraise plans

→There was no specific mention of any current or planned fundraising through debt or equity in the call.
→The company highlighted having one of the strongest balance sheets and strong growth momentum.
→Management expressed being very selective on inorganic growth opportunities rather than urgently pursuing external funding.
→Upcoming capex plans primarily relate to internal expansions like Plant-6, with details to be shared by end of March.
→No timelines or concrete plans were provided regarding raising funds through debt or equity at this stage.

Order book

Yes

→The injectable facility has already received GMP certification and is undergoing customer audits primarily in Q4 FY '25 and possibly Q1 FY '26.
→There is already some order book in place for existing production, with products ready for commercialization and out of stability batches.
→The company sees good momentum and very positive responses from audits and queries on the injectable product portfolio.
→Exact timing on reaching peak capacity or solid order numbers is uncertain due to the incubation period and the B2B nature of order flow.
→The company emphasizes a steady buildup in order inflow as audits complete and customers initiate larger orders.
→Overall, the order pipeline is promising but still in the early commercialization phase for injectables.

Capex plans

Yes

→Upcoming capex primarily focuses on Plant-6, which involves oral solid expansion; currently in layout and machinery selection phase (comment expected by end of March call).
→Expansion alongside Plant-6 and Plant-2 extension aims to reach INR 1,000 crores revenue.
→Recent brownfield acquisition of Plant-6 will be built out to support growth.
→Expansion strategy follows a 2-3 year window rather than a longer 5-6 year timeline.
→Additional capex expected for Plant-6 to support scaling oral solids beyond current capacity.
→Continuing investments in existing facilities, including Plant-3 capex mostly clocked in FY '25.
→Focus on maintaining ROCE around 25%-28% despite capex increases.
→Management remains selective on inorganic growth opportunities, prioritizing strategic fit and avoiding hidden risks.

How does Windlas Biotech Ltd rank vs peers in ?

Pro feature

1Windlas Biotech Ltd

Rev 2Mar 3

See full sector rankings

Want more stocks like Windlas Biotech Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio